References
World Health Organisation. Dementia fact sheet December 2017; https://doi.org/www.un.org/en/development/desa/population/publications/pdf/ageing/WPA2015_Report.pdf.
Gauthier S, Molineovo J.L. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer’s disease. Alzheimer’s Dement. 2013, 9: 326–331.
Cummings J, Lee G, Ritter A, Zhong K. Alzheimer’s disease drug development pipeline:2018. Alzheimer’s Dement Transl Res Clin Interv 2018;4:195–214.
Tariot PN, Lopera F, Langbaum JB, Thomas RG, Hendrix S, Schneider LS, et al. The Alzheimer’s Prevention Initiative Autosomal-Dominant Alzheimer’s Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer’s disease, including a placebo-treated noncarrier cohort. Alzheimers’s Disease 2018;4:150–160.
Messmer MF, Wilhelm EE, Shoulson I. I-SPY 2 Breast Cancer Trial as a Model for Innovation in Alzheimer Disease Therapies. JAMA Neurol. 2017;74:1027–1028.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bakchine, S. Treating Alzheimer’s Disease : Combine or Fail ?. J Prev Alzheimers Dis 6, 174–176 (2019). https://doi.org/10.14283/jpad.2019.16
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14283/jpad.2019.16